Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of -7.69% [1] - The company posted revenues of $12.81 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.13% and down from $13.54 million a year ago [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Movement and Outlook - The stock has increased approximately 70.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.1% [3] - The future price movement of the stock will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $14.03 million, and for the current fiscal year, it is -$0.63 on revenues of $46.1 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 40% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]